June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Long term visual and anatomic outcomes of switching to Aflibercept for neovascular AMD : 2 years results.
Author Affiliations & Notes
  • David Sayag
    Ophthalmology Eye Clinic, Creteil Eye Clinic Univ Hospital, Paris, France
    Paris Retina Vision, Paris, France
  • Mayer Srour
    Ophthalmology Eye Clinic, Creteil Eye Clinic Univ Hospital, Paris, France
    Paris Retina Vision, Paris, France
  • Oudy Semoun
    Ophthalmology Eye Clinic, Creteil Eye Clinic Univ Hospital, Paris, France
    Paris Retina Vision, Paris, France
  • Neda Abraham
    Foch Hospital, Suresnes, France
  • Vincent Pierre-Kahn
    Foch Hospital, Suresnes, France
    Paris Retina Vision, Paris, France
  • Footnotes
    Commercial Relationships   David Sayag, None; Mayer Srour, None; Oudy Semoun, None; Neda Abraham, None; Vincent Pierre-Kahn, None
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 440. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      David Sayag, Mayer Srour, Oudy Semoun, Neda Abraham, Vincent Pierre-Kahn; Long term visual and anatomic outcomes of switching to Aflibercept for neovascular AMD : 2 years results.
      . Invest. Ophthalmol. Vis. Sci. 2017;58(8):440.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To report interim 2-year visual and anatomic outcomes of intravitreal aflibercept for neovascular age-related macular degeneration (AMD) in patients recurrent or refractory to ranibizumab.

Methods : This is a retrospective review of eyes with neovascular AMD with at least 2 years of follow-up after the switch. All Patients has had a minimum of 3 injections of ranibizumab before the switch. Aflibercept was used in recurrent or refractory patients to ranibizumab. Changes in best corrected visual acuity ( BVCA), fluid ,central retinal thickness , anatomic outcome of ellipsoid ( , retinal pigment epithelium (RPE) and external limiting membrane (ELM) on optical coherence tomography (OCT) were described .Frequency of injections were also analyzed

Results : 125 eyes on110 patients were studied. Mean age of patients was 79 years . Before switching, patients had received a mean of 7,7 injections of ranibizumab (3-30). At baseline BCVA was 49,9 letters and the mean CRT 388,3 µm. 153 (87%) eyes showed a pigment epithelial detachment. Intraretinal fluid (IFR) was present in 59 % of eyes. Sub-retinal fluid was present in 65% of eyes. mean follow up duration after the first injection of aflibercept was 24 months. One year after the switch, an interim analysis shows a nonsignificant increase of + 2,3 letters (p=0,454) with a mean number of 3,9 Aflibercept injections (65 eyes analyzed) and a mean change in CRT of -59,5 µm (p<0,0001 ; 145 eyes analyzed). Two years after the switch, an interim analysis shows a mean change in visual acuity of -0,3 letters (p=0,633) with a mean of 6,1 injections of aflibercept and a mean change in CRT of -76,1 µm (p<0,0001 ; 55 eyes analyzed). At 24 months, ELM and RPE disruption were shown in 75% and 63% without correlation with final BVCA.

Conclusions : Two years after a switch to aflibercept for nAMD in patients recurrent or refractory to ranibizumab, an interim analysis shows that visual acuity was stabilized and CRT had a significant improvement (p<0,0001). Moreover ELM and RPE disruption are frequent after long term switching clinical practice

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×